GgoogleUS BusinessMarkets first seen 20 d ago, last 15 h ago, peak #3
SELLAS Life Sciences hits 80th event in leukemia trial
Original: sls stock
SELLAS Life Sciences announced its Phase 3 REGAL trial of galinpepimut-S in acute myeloid leukemia has reached its 80th event, a key milestone that brings the study closer to its data analysis stage. Investors are watching the biotech stock closely as the trial progresses toward potential results that could shape the company's regulatory prospects.
Why now: The Phase 3 trial milestone is moving investors to check the stock ahead of anticipated trial outcomes.
SELLAS Life Sciencesgalinpepimut-SREGAL trialacute myeloid leukemia
Evidence
- Lilly’s new $1.5B acquisition is a preclinical Massachusetts biotech · The Business Journals
- Sellas Life Sciences Reaches 80Th Event In Phase 3 Regal Trial Of Galinpepimut-S (Gps) In Acute Myeloid Leukemia · TradingView
Elsewhere
API: https://socialmediatrends-api.osmike.com/v1/trends/3996400